NTLA
Intellia Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.64B
P/E Ratio
—
EPS
$-3.81
Beta
1.99
52W High
$28.25
52W Low
$6.65
50-Day MA
$13.10
200-Day MA
$12.81
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
-0.10
About Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $67.67M |
| Gross Profit (TTM) | $-256.78M |
| EBITDA | $-431.22M |
| Operating Margin | -428.90% |
| Return on Equity | -53.50% |
| Return on Assets | -27.10% |
| Revenue/Share (TTM) | $0.62 |
| Book Value | $5.77 |
| Price-to-Book | 2.31 |
| Price-to-Sales (TTM) | 24.21 |
| EV/Revenue | 17.63 |
| EV/EBITDA | -5.51 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 78.80% |
| Shares Outstanding | $118.13M |
| Float | $111.94M |
| % Insiders | 4.61% |
| % Institutions | 85.41% |
Analyst Ratings
Consensus ($25.29 target)
1
Strong Buy11
Buy11
Hold1
Sell1
Strong SellData last updated: 4/9/2026